Simvastatin Reduces Circulating Plasminogen Activator Inhibitor 1 Activity in Volunteers with the Metabolic Syndrome | Zendy

Long Wang | Zendy; Jason Rockwood | Zendy; Danielle Zak | Zendy; Sridevi Devaraj | Zendy; Ishwarlal Jialal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Simvastatin Reduces Circulating Plasminogen Activator Inhibitor 1 Activity in Volunteers with the Metabolic Syndrome

Author(s) -

Long Wang,

Jason Rockwood,

Danielle Zak,

Sridevi Devaraj,

Ishwarlal Jialal

Publication year - 2008

Publication title -

metabolic syndrome and related disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.598

H-Index - 45

eISSN - 1557-8518

pISSN - 1540-4196

DOI - 10.1089/met.2008.0012

Subject(s) - medicine , simvastatin , metabolic syndrome , plasminogen activator inhibitor 1 , plasminogen activator , pharmacology , endocrinology , diabetes mellitus

The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that simvastatin has concomitant benefits in reducing low-density lipoprotein (LDL)-cholesterol and inflammation in MS subjects. The levels of plasminogen activator inhibitor 1(PAI-1), soluble P-selectin (sP-selectin), and soluble CD40 ligand (sCD40L) play an important role in the development and progression of atherosclerosis. Their levels are increased in the MS. The current study was to investigate the effects of simvastatin on PAI-1, sP-selectin, and sCD40 ligand.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research